|
MechanismTubulin inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date17 Jun 2010 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date19 May 2004 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date16 Jun 1999 |
A multicenter, randomized, open label, two treatment, two period,two sequence, single-dose, crossover, bioequivalence study ofMethotrexate Tablets 2.5 mg (manufactured for Actavis LLC) withMethotrexate Tablets USP 2.5 mg (DAVA Pharmaceuticals, Inc.,Fort Lee, NJ 07024 USA) in patients with mild to severe psoriasisor rheumatoid arthritis (RA), who are already on establishedregimens of 2.5 mg every 12 hours under fasting condition. - NA
A randomized, open label, multi centric, two treatment, two period, two sequence, single dose, crossover, bioequivalence study of Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial manufactured by Sindan Pharma for Actavis LLC, USA and Abraxane 100 mg/vial (Albumin bound Paclitaxel 260 mg/m2) intravenous infusion Abraxis BioScience LLC, New Jersey in patients with metastatic breast cancer
100 Clinical Results associated with Actavis South Atlantic LLC
0 Patents (Medical) associated with Actavis South Atlantic LLC
100 Deals associated with Actavis South Atlantic LLC
100 Translational Medicine associated with Actavis South Atlantic LLC